JP2017031160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017031160A5 JP2017031160A5 JP2016163087A JP2016163087A JP2017031160A5 JP 2017031160 A5 JP2017031160 A5 JP 2017031160A5 JP 2016163087 A JP2016163087 A JP 2016163087A JP 2016163087 A JP2016163087 A JP 2016163087A JP 2017031160 A5 JP2017031160 A5 JP 2017031160A5
- Authority
- JP
- Japan
- Prior art keywords
- history
- months
- subject
- vegf antibody
- capecitabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000306 recurrent effect Effects 0.000 claims description 12
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 206010053567 Coagulopathies Diseases 0.000 claims description 5
- 206010016717 Fistula Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000003187 abdominal effect Effects 0.000 claims description 5
- 208000003455 anaphylaxis Diseases 0.000 claims description 5
- 208000015294 blood coagulation disease Diseases 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000003890 fistula Effects 0.000 claims description 5
- 230000002008 hemorrhagic effect Effects 0.000 claims description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
- 230000036210 malignancy Effects 0.000 claims description 5
- 238000002625 monoclonal antibody therapy Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010034649 Peritoneal abscess Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 238000002271 resection Methods 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 15
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 15
- 229960004117 capecitabine Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 11
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 8
- 229960000397 bevacizumab Drugs 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 206010038111 Recurrent cancer Diseases 0.000 claims 7
- 230000004083 survival effect Effects 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 238000011226 adjuvant chemotherapy Methods 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000009852 coagulant defect Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 238000011227 neoadjuvant chemotherapy Methods 0.000 claims 4
- 230000001052 transient effect Effects 0.000 claims 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 238000011269 treatment regimen Methods 0.000 claims 2
- 206010060921 Abdominal abscess Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012325 curative resection Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11710208P | 2008-11-22 | 2008-11-22 | |
| US61/117,102 | 2008-11-22 | ||
| US17800909P | 2009-05-13 | 2009-05-13 | |
| US61/178,009 | 2009-05-13 | ||
| US17930709P | 2009-05-18 | 2009-05-18 | |
| US61/179,307 | 2009-05-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537663A Division JP6041489B2 (ja) | 2008-11-22 | 2009-11-20 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018080848A Division JP2018138583A (ja) | 2008-11-22 | 2018-04-19 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017031160A JP2017031160A (ja) | 2017-02-09 |
| JP2017031160A5 true JP2017031160A5 (OSRAM) | 2020-02-27 |
| JP6850562B2 JP6850562B2 (ja) | 2021-03-31 |
Family
ID=42154236
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537663A Active JP6041489B2 (ja) | 2008-11-22 | 2009-11-20 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2016163087A Active JP6850562B2 (ja) | 2008-11-22 | 2016-08-23 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2018080848A Withdrawn JP2018138583A (ja) | 2008-11-22 | 2018-04-19 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2020076277A Pending JP2020128389A (ja) | 2008-11-22 | 2020-04-22 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537663A Active JP6041489B2 (ja) | 2008-11-22 | 2009-11-20 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018080848A Withdrawn JP2018138583A (ja) | 2008-11-22 | 2018-04-19 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2020076277A Pending JP2020128389A (ja) | 2008-11-22 | 2020-04-22 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20100143351A1 (OSRAM) |
| EP (3) | EP2752189B1 (OSRAM) |
| JP (4) | JP6041489B2 (OSRAM) |
| KR (3) | KR20170015525A (OSRAM) |
| CN (2) | CN102223897B (OSRAM) |
| AR (1) | AR074203A1 (OSRAM) |
| AU (1) | AU2009316409A1 (OSRAM) |
| BR (1) | BRPI0916138A2 (OSRAM) |
| CA (1) | CA2744158A1 (OSRAM) |
| CL (1) | CL2011001186A1 (OSRAM) |
| CY (1) | CY1118549T1 (OSRAM) |
| DK (2) | DK2361085T4 (OSRAM) |
| ES (2) | ES2535404T5 (OSRAM) |
| HR (1) | HRP20170059T1 (OSRAM) |
| HU (2) | HUE024872T2 (OSRAM) |
| IL (2) | IL212998A (OSRAM) |
| LT (1) | LT2752189T (OSRAM) |
| MX (2) | MX2011005383A (OSRAM) |
| PH (1) | PH12014502507A1 (OSRAM) |
| PL (2) | PL2361085T5 (OSRAM) |
| PT (1) | PT2752189T (OSRAM) |
| RU (1) | RU2531948C2 (OSRAM) |
| SG (1) | SG171780A1 (OSRAM) |
| SI (2) | SI2361085T2 (OSRAM) |
| SM (1) | SMT201700173T1 (OSRAM) |
| TW (2) | TWI612971B (OSRAM) |
| WO (1) | WO2010059969A2 (OSRAM) |
| ZA (1) | ZA201103321B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| KR20170015525A (ko) | 2008-11-22 | 2017-02-08 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도 |
| MX2012009554A (es) | 2010-02-23 | 2012-11-23 | Hoffmann La Roche | Terapia anti-angiogenesis para el tratamiento del cancer ovarico. |
| FI4241849T3 (fi) * | 2011-10-14 | 2024-11-12 | Hoffmann La Roche | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote |
| HK1200716A1 (zh) | 2011-11-01 | 2015-08-14 | 细胞基因公司 | 使用胞苷類似物的口服製劑治療癌症的方法 |
| MX365139B (es) | 2012-03-13 | 2019-05-24 | Hoffmann La Roche | Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino. |
| HUE064634T2 (hu) | 2013-08-26 | 2024-04-28 | Novartis Ag | Kardiovaszkuláris betegségek kezelése |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3119397B1 (en) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3164154A1 (en) * | 2014-07-03 | 2017-05-10 | Imclone, LLC | Combination therapy |
| JP6742297B2 (ja) | 2014-07-14 | 2020-08-19 | ユニヴァーシティ オブ ユタ リサーチ ファンデーション | その場凝固複合コアセルベートならびにその製造および使用方法 |
| CN104991065B (zh) * | 2015-07-07 | 2017-01-11 | 复旦大学附属金山医院 | 一种用于诊断乳腺癌的三联标志物及其应用 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| WO2019084548A1 (en) * | 2017-10-27 | 2019-05-02 | University Of Utah Research Foundation | COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS |
| JP7410876B2 (ja) | 2018-01-26 | 2024-01-10 | フルイデックス メディカル テクノロジー，リミティッド ライアビリティ カンパニー | 血管閉塞のためにその場凝固複合コアセルベートを使用する装置及び方法 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| WO2019173843A1 (en) * | 2018-03-09 | 2019-09-12 | The Regents Of The University Of California | Combination treatment of chemoresistant cancers |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN111710425A (zh) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 |
| CN120344271A (zh) * | 2023-01-19 | 2025-07-18 | 江苏恒瑞医药股份有限公司 | 抗her2抗体药物偶联物治疗乳腺癌 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| SI1695985T1 (sl) | 1997-04-07 | 2011-06-30 | Genentech Inc | Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| WO2006014729A2 (en) | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN103143017A (zh) * | 2006-12-19 | 2013-06-12 | 基因技术公司 | 用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂 |
| AU2008210521A1 (en) * | 2007-02-01 | 2008-08-07 | Genentech, Inc. | Combination therapy with angiogenesis inhibitors |
| KR20170015525A (ko) * | 2008-11-22 | 2017-02-08 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도 |
| US11379945B2 (en) | 2019-02-27 | 2022-07-05 | Google Llc | Grayscale histogram generation |
-
2009
- 2009-11-20 KR KR1020177002172A patent/KR20170015525A/ko not_active Ceased
- 2009-11-20 PT PT131897118T patent/PT2752189T/pt unknown
- 2009-11-20 DK DK09764134.4T patent/DK2361085T4/en active
- 2009-11-20 EP EP13189711.8A patent/EP2752189B1/en not_active Revoked
- 2009-11-20 US US12/623,297 patent/US20100143351A1/en not_active Abandoned
- 2009-11-20 TW TW104125142A patent/TWI612971B/zh not_active IP Right Cessation
- 2009-11-20 SM SM20170173T patent/SMT201700173T1/it unknown
- 2009-11-20 TW TW098139537A patent/TWI542359B/zh not_active IP Right Cessation
- 2009-11-20 KR KR1020187030405A patent/KR20180117734A/ko not_active Ceased
- 2009-11-20 PL PL09764134T patent/PL2361085T5/pl unknown
- 2009-11-20 SI SI200931187T patent/SI2361085T2/sl unknown
- 2009-11-20 MX MX2011005383A patent/MX2011005383A/es active IP Right Grant
- 2009-11-20 CN CN200980146589.3A patent/CN102223897B/zh not_active Expired - Fee Related
- 2009-11-20 AU AU2009316409A patent/AU2009316409A1/en not_active Abandoned
- 2009-11-20 PL PL13189711T patent/PL2752189T3/pl unknown
- 2009-11-20 CA CA2744158A patent/CA2744158A1/en not_active Abandoned
- 2009-11-20 CN CN201510520134.0A patent/CN105214086B/zh not_active Expired - Fee Related
- 2009-11-20 EP EP16188246.9A patent/EP3178478A1/en not_active Withdrawn
- 2009-11-20 JP JP2011537663A patent/JP6041489B2/ja active Active
- 2009-11-20 MX MX2014002003A patent/MX340724B/es unknown
- 2009-11-20 KR KR1020117014272A patent/KR101807319B1/ko not_active Expired - Fee Related
- 2009-11-20 AR ARP090104477A patent/AR074203A1/es unknown
- 2009-11-20 SI SI200931591T patent/SI2752189T1/sl unknown
- 2009-11-20 SG SG2011036696A patent/SG171780A1/en unknown
- 2009-11-20 ES ES09764134.4T patent/ES2535404T5/es active Active
- 2009-11-20 HU HUE09764134A patent/HUE024872T2/en unknown
- 2009-11-20 WO PCT/US2009/065381 patent/WO2010059969A2/en not_active Ceased
- 2009-11-20 LT LTEP13189711.8T patent/LT2752189T/lt unknown
- 2009-11-20 RU RU2011125518/15A patent/RU2531948C2/ru active
- 2009-11-20 EP EP09764134.4A patent/EP2361085B9/en not_active Not-in-force
- 2009-11-20 ES ES13189711.8T patent/ES2611337T3/es active Active
- 2009-11-20 HU HUE13189711A patent/HUE032693T2/en unknown
- 2009-11-20 BR BRPI0916138A patent/BRPI0916138A2/pt not_active Application Discontinuation
- 2009-11-20 DK DK13189711.8T patent/DK2752189T3/en active
-
2011
- 2011-05-06 ZA ZA2011/03321A patent/ZA201103321B/en unknown
- 2011-05-19 IL IL212998A patent/IL212998A/en active IP Right Grant
- 2011-05-20 CL CL2011001186A patent/CL2011001186A1/es unknown
-
2014
- 2014-11-10 PH PH12014502507A patent/PH12014502507A1/en unknown
-
2015
- 2015-05-15 US US14/714,177 patent/US20150246124A1/en not_active Abandoned
-
2016
- 2016-01-21 IL IL243741A patent/IL243741A0/en unknown
- 2016-05-13 US US15/154,797 patent/US20160243227A1/en not_active Abandoned
- 2016-08-23 JP JP2016163087A patent/JP6850562B2/ja active Active
- 2016-12-20 US US15/385,602 patent/US20170100478A1/en not_active Abandoned
-
2017
- 2017-01-16 HR HRP20170059TT patent/HRP20170059T1/hr unknown
- 2017-01-25 CY CY20171100116T patent/CY1118549T1/el unknown
-
2018
- 2018-04-19 JP JP2018080848A patent/JP2018138583A/ja not_active Withdrawn
-
2020
- 2020-04-22 JP JP2020076277A patent/JP2020128389A/ja active Pending
- 2020-05-15 US US16/874,936 patent/US20210093715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017031160A5 (OSRAM) | ||
| JP2012509889A5 (OSRAM) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2013520442A5 (OSRAM) | ||
| JP2022009090A5 (OSRAM) | ||
| JP2022121594A5 (OSRAM) | ||
| JP2013173775A5 (OSRAM) | ||
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2020521797A5 (OSRAM) | ||
| JP2021512149A (ja) | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 | |
| JPWO2020111018A5 (OSRAM) | ||
| JP2019524820A5 (OSRAM) | ||
| JP2016094450A5 (OSRAM) | ||
| JP2024016209A5 (OSRAM) | ||
| RU2012109932A (ru) | Антиангиогенная терапия для лечения ранее подвергавшегося лечению рака молочной железы | |
| WO2019016928A1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| JP2020535180A5 (OSRAM) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| TWI535436B (zh) | 腫瘤治療用醫藥組合製劑 | |
| Miyata et al. | Fatal pulmonary veno-occlusive disease after chemotherapy for Burkitt's lymphoma. | |
| EP3733202A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| JP6143169B2 (ja) | 膵臓癌治療剤 |